Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment available for various hematological malignancies. Ideally, prospective randomized controlled trials (RCTs) should establish the indications for allo-HSCT. In reality, however, RCTs are not feasible due to the rarity of many hematological conditions. In these scenarios, decision analysis, which simulates possible outcomes with different approaches, can help in selecting the treatment strategy predicted to have the best result. Assessment of cost-effectiveness can also be incorporated in computational simulation analysis. In this review, we would like to provide an overview of decision-analytic models that evaluate alternative treatment strategies for patients with hematological malignancies.

中文翻译：

---

决策分析模型可作为血液恶性肿瘤患者选择结合造血干细胞移植的最佳疗法的工具。

同种异体造血干细胞移植（allo-HSCT）是可用于各种血液系统恶性肿瘤的唯一治疗方法。理想情况下，前瞻性随机对照试验（RCT）应该确定allo-HSCT的适应症。然而，实际上，由于许多血液学疾病的稀有性，RCT不可行。在这些情况下，决策分析可以使用不同的方法模拟可能的结果，可以帮助选择预期效果最佳的治疗策略。成本效益评估也可以纳入计算仿真分析中。在这篇综述中，我们将提供决策分析模型的概述，该模型评估血液系统恶性肿瘤患者的替代治疗策略。